NVO icon

Novo Nordisk

65.16 USD
+2.54
4.06%
At close Apr 29, 4:00 PM EDT
After hours
64.95
-0.21
0.32%
1 day
4.06%
5 days
5.49%
1 month
-6.16%
3 months
-22.46%
6 months
-41.81%
Year to date
-25.55%
1 year
-48.64%
5 years
106.73%
10 years
134.39%
 

About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 76,302

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

6% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.21B

0.07% more ownership

Funds ownership: 9.87% [Q3] → 9.94% (+0.07%) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 588 | Existing positions reduced: 639

7% less funds holding

Funds holding: 1,765 [Q3] → 1,634 (-131) [Q4]

24% less capital invested

Capital invested by funds: $39.6B [Q3] → $30.1B (-$9.52B) [Q4]

31% less first-time investments, than exits

New positions opened: 197 | Existing positions closed: 285

49% less funds holding in top 10

Funds holding in top 10: 61 [Q3] → 31 (-30) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$64
2%
downside
Avg. target
$64
2%
downside
High target
$64
2%
downside

1 analyst rating

positive
0%
neutral
100%
negative
0%
BMO Capital
Evan David Seigerman
17% 1-year accuracy
3 / 18 met price target
2%downside
$64
Market Perform
Downgraded
17 Apr 2025

Financial journalist opinion

Based on 88 articles about NVO published over the past 30 days

Negative
Seeking Alpha
2 hours ago
Growth Is Priced Out Of Novo Nordisk
A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I believe the market has overshot to the downside. Not all is lost, and there are additional efforts the company is making to stay relevant, ranging from new trials of CagriSema and higher doses of semaglutide, to external innovation.
Growth Is Priced Out Of Novo Nordisk
Positive
Proactive Investors
4 hours ago
Hims & Hers stock pops on Novo Nordisk partnership
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Hims & Hers stock pops on Novo Nordisk partnership
Positive
Benzinga
5 hours ago
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Neutral
CNBC International TV
5 hours ago
Pharma firms maastraz
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Pharma firms maastraz
Neutral
Zacks Investment Research
6 hours ago
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Positive
Fox Business
6 hours ago
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Positive
Schaeffers Research
6 hours ago
Hims & Hers Stock Rides Wegovy Wave Higher
Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 22.6% at $34.92 at last glance, after news that the telehealth platform will offer Novo Nordisk's (NVO) popular weight-loss drug, Wegovy.
Hims & Hers Stock Rides Wegovy Wave Higher
Positive
Seeking Alpha
6 hours ago
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Neutral
Schwab Network
6 hours ago
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the latest company following a formula.
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Positive
Investors Business Daily
7 hours ago
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy
Hims stock launched Tuesday after the company inked a deal to offer Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform.
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy
Charts implemented using Lightweight Charts™